• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Time And Sales Reporter
Editor's PickInvesting

Journavx: A Promising Opioid Alternative, but Not a Silver Bullet

by January 31, 2025
January 31, 2025

Jeffrey A. Singer

Prescription

On January 30, the Food and Drug Administration announced it approved the first of a new class of pain reliever drugs as an alternative to opioids. Journavx (generic name suzetrigine) was found to work as well as hydrocodone (Vicodin, Norco) to treat moderate to severe postoperative pain in two Phase 3 clinical trials, one with patients who underwent bunionectomy surgery and another on patients who underwent abdominoplasty. 

The drug is unique in that, unlike opioids, which directly target the brain to dull the perception of pain, or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, which reduce inflammation and pain at the injury site, suzetrigine blocks the nerves that transmit pain signals to the brain.

The Phase 1 trials of suzetrigine took place in 2021. The entire approval process took only about four years, which is not typical for the FDA. The process usually takes about 10–15 years, and the Phase 1–3 clinical trials process generally takes around 6–7 years, followed by 10 months for standard FDA review (6 months for accelerated review). According to a report from the trade association BIO, 90 percent of drugs don’t make it through the Phase 1 approval process. A 2024 study published in the Journal of the American Medical Association estimated the mean cost of bringing a drug to market from 2000 to 2018 to be “$879.3 million when both drug development failure and capital costs were included.”

The FDA accelerated suzetrigine’s approval through its Overdose Prevention Framework, streamlining the clinical trial and approval process for opioid substitutes and harm-reduction products such as overdose antidotes. This demonstrates that the FDA can dramatically reduce the regulatory burden on new drug development when it deems a problem urgent. However, the FDA—not the patients suffering from specific conditions—decides what qualifies as urgent.

The FDA created the accelerated framework based on the debunked narrative that the overdose crisis was caused by doctors hooking their patients on opioids. As I have written, the overdose crisis resulted from a growing population of nonmedical drug users accessing drugs in the increasingly dangerous black market caused by drug prohibition. Substance Abuse and Mental Health Services Administration (SAMHSA) surveys begun in 2002 consistently show the addiction rate to prescription pain pills has never exceeded 0.8 percent of adults over age 18 (see attached graph). 

As early as 2017, I pointed out that overdose rates began to climb as doctors started cutting back on opioid prescribing, which reduced nonmedical users’ access to diverted pain pills and drove them to more dangerous heroin and, now, fentanyl.

drugs

Nevertheless, Journavx appears to be a real breakthrough drug, opening the door for a new class of pain relievers for patients to access. This is good news.

A caveat: Pain is subjective, and analgesics affect individuals differently. The clinical trials found it roughly equivalent to a standard dose of hydrocodone. Hydrocodone is not as potent as oxycodone and doesn’t work for everyone, though it works for many people.

Clinicians must still be ready to prescribe oxycodone or something even more potent if this new drug fails to provide the relief patients require. I worry that many doctors might resort to prescribing this drug exclusively and abandon opioid alternatives altogether due to fear of disciplinary action from cops practicing medicine.

previous post
Should the US Respond to “Unfair” Trade Practices?
next post
‘Essential to our nation’s sovereignty’: Noncitizen voter crackdown led by GOP ahead of 2026 midterms

Related Posts

Procter & Gamble to cut 7,000 jobs as...

June 7, 2025

Top 5 Canadian Mining Stocks This Week: Africa...

June 7, 2025

Crypto Market Recap: Strategy Eyes US$1 Billion Capital...

June 7, 2025

Ford Government Pushes Bill 5 Through Legislature, Sparking...

June 7, 2025

Hempalta Provides Strategic Update Regarding Equipment Sale and...

June 7, 2025

Editor’s Picks: Marathon Project Gets Nod, Rio Tinto...

June 7, 2025







    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.




    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 7, 2025
    • Silver’s Surge is No Fluke—Here’s the Strange Ratio Driving It

      June 7, 2025
    • Everyone Talks About Leaving a Better Planet for Our Children: Why Don’t We Leave Better Children for Our Planet?

      June 7, 2025
    • Big Rally Ahead Should Yield All-Time High on This Index

      June 7, 2025
    • Your Weekly Stock Market Snapshot: What It Means for Your Investments

      June 7, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 timeandsalesreporter.com | All Rights Reserved

    Time And Sales Reporter
    • World News
    • Politics
    • Stock
    • Investing
    • Editor’s Pick

    Read alsox

    Westport Announces Lock-Up Agreements in Support of the...

    May 1, 2025

    Capital One and Discover merger approved by Federal...

    April 20, 2025

    Uranium Stocks: 5 Biggest Companies in 2025

    May 20, 2025